DERRINGER FENTON: Open Payments
NPI 1386211308 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,199 in 65 payments from 17 companies in 2025. Trend: 2023 $708 · 2024 $238 · 2025 $1,199
Food & beverage: $1,098Education: $101
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $236 |
| Teva Pharmaceuticals USA, Inc. | 13 | $216 |
| Neurocrine BioSciences, Inc. | 8 | $207 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Alkermes, Inc. | 4 | $82 |
| Braeburn Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $50 |
| ViiV Healthcare Company | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $30 |
Products named: INGREZZA, VRAYLAR, AUSTEDO XR, MAVYRET, ARISTADA, ABILIFY ASIMTUFII, BRIXADI, REXULTI.
Industry payments across MO — which companies pay providers there.
